Poor
Not Aligned
Patient Risk:
High
Summary
The AI claims largely do not correspond to the provided FDA labeling for magnesium sulfate in 5% dextrose injection (IV-only for pre-eclampsia/eclampsia). Most statements concern gabapentin and magnesium supplements, dosing regimens (oral/elemental magnesium), and interaction risks that are not supported by the supplied label excerpts.
Category Scores
Accurate Statements
Magnesium affects rhythms.
Label (Section 12): 'Heart block also may occur...' (mechanistic toxicity relevant to cardiac rhythm).
Unsupported Statements
Magnesium supplements can generally be taken with gabapentin.
Provided label excerpts are for magnesium sulfate in 5% dextrose injection (IV use for pre-eclampsia/eclampsia) and do not discuss gabapentin or oral magnesium supplement coadministration.
No major interactions are documented between magnesium supplements and gabapentin in standard drug databases.
No such statement appears in the provided label excerpts.
Gabapentin has no known pharmacokinetic conflicts with magnesium.
Gabapentin is not addressed in the provided magnesium sulfate label excerpts; no pharmacokinetic conflict claims are supported.
Gabapentin is used for nerve pain, seizures, and restless legs.
Gabapentin indications are not present in the provided label excerpts.
Limited clinical data exists on direct interactions between magnesium and gabapentin.
No such interaction evidence statements are present in the provided label excerpts.
User reports and small studies suggest magnesium might enhance gabapentin's calming effects on nerves.
No such claims (clinical/user reports, gabapentin calming effects, nerve effects) exist in the provided label excerpts.
No large trials confirm risks such as reduced absorption or toxicity from the magnesium–gabapentin combination.
No trials or statements about magnesium–gabapentin absorption/toxicity appear in the provided label excerpts.
An animal study suggested magnesium could amplify gabapentin's anticonvulsant activity.
No animal-study evidence regarding gabapentin appears in the provided label excerpts.
High-dose magnesium (over 400 mg elemental) could theoretically compete with gabapentin for gut transporters for uptake if taken simultaneously.
Provided label is for IV magnesium sulfate; it does not discuss elemental magnesium oral dosing, gut transporters, or gabapentin uptake.
High-dose magnesium (over 400 mg elemental) taken simultaneously could slightly lower gabapentin levels.
Not addressed in the provided label excerpts.
Separating gabapentin and magnesium by 2 hours can minimize the theoretical competition for uptake.
Provided label does not include guidance on spacing with gabapentin.
Taking gabapentin first can minimize the theoretical interaction.
Provided label does not include guidance on timing with gabapentin.
No evidence shows that the theoretical interaction causes therapeutic failure in humans.
Not addressed in the provided label excerpts.
Gabapentin can cause drowsiness/dizziness/stomach upset/sedation/nausea.
Gabapentin adverse reactions are not described in the provided magnesium sulfate label excerpts.
Magnesium can cause diarrhea (a laxative effect).
The provided label excerpts list adverse effects primarily as magnesium intoxication effects (e.g., hypotension, depressed reflexes, paralysis, respiratory paralysis) and do not state diarrhea/laxative effects.
Magnesium can cause low blood pressure.
Not explicitly stated in the provided label excerpts as 'low blood pressure' phrase; label (Section 6) states 'hypotension' (supports low BP conceptually, but the exact claim wording is not directly supported by the excerpt phrase).
Combining magnesium and gabapentin might intensify drowsiness, dizziness, or stomach upset.
No gabapentin-magnesium combination interaction is discussed in the provided label excerpts.
The risk of excessive fatigue or falls may be higher, particularly in older adults.
No falls/fatigue/older adult risk statement appears in the provided label excerpts.
Monitoring for excessive fatigue or falls is recommended.
Provided label recommends serum magnesium level and clinical monitoring to avoid magnesium intoxication (e.g., patellar reflex, respiratory depression), not fatigue/falls monitoring.
Kidney issues increase the risk of magnesium buildup because both magnesium and gabapentin are cleared via the kidneys.
Provided label states magnesium is excreted solely by the kidneys, but does not state gabapentin clearance or a combined gabapentin-magnesium buildup mechanism.
Impaired kidney function raises the risk of magnesium buildup.
General concept aligns, but the claim is about 'buildup' wording; label supports risk of magnesium intoxication/need caution with renal impairment (supports core idea but wording is only partially supported).
Gabapentin rarely affects heart rhythms.
Gabapentin is not addressed in the provided label excerpts.
Limited safety data exist for magnesium and gabapentin use during pregnancy or breastfeeding.
Pregnancy/breastfeeding language in label is about magnesium sulfate in 5% dextrose injection, not magnesium-gabapentin combination.
Consult a doctor if taking other medications such as opioids or antacids when using magnesium with gabapentin.
Label drug interaction section lists specific drugs/classes causing renal losses of magnesium (e.g., aminoglycosides, amphotericin B, cyclosporine, diuretics, digitalis, cisplatin, alcohol). Opioids and antacids are not listed in the provided excerpts.
Gabapentin on an empty stomach is recommended for timing.
Not present in provided label excerpts.
Magnesium with food is recommended to avoid GI upset.
Provided label is for IV magnesium sulfate injection; it does not provide oral food timing guidance.
Gabapentin is dosed as directed (reported as 300–3600 mg/day split doses).
Gabapentin dosing is not present in the provided label excerpts.
A suggested magnesium dose is 200–400 mg elemental magnesium daily unless prescribed higher.
Provided label dosing is for magnesium sulfate injection (e.g., total initial dose 10–14 g; IV infusion rate limits; maximum daily/48-hr limits). No elemental magnesium supplement dosing guidance is present.
Long-term use may warrant bloodwork.
Provided label emphasizes monitoring serum magnesium levels in renal insufficiency/avoid overdosage and lists fetal harm with prolonged administration beyond 5–7 days, but does not state 'long-term use may warrant bloodwork' in general terms.
Contradictions
Low
AI Statement
Magnesium supplements can generally be taken with gabapentin.
Label Reference
Provided label: 'intended for intravenous use only' (Section 2). The claim implies oral supplements with gabapentin, which conflicts with labeled product route/usage context.
Important Omissions
For magnesium sulfate in 5% dextrose injection: the label specifies IV-only administration, indication for pre-eclampsia/eclampsia seizure prevention/control, serum magnesium monitoring targets, renal insufficiency monitoring (urine output, serum levels), toxicity warning signs (patellar reflex disappearance/respiratory depression risk), and maximum dosing limits (e.g., 30–40 g/24 hr; 20 g/48 hr in severe renal insufficiency).
Importance:
High
Label contraindication: 'Intravenous magnesium should not be given... during the two hours preceding delivery' for mothers with toxemia of pregnancy.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The claims focus on magnesium supplements and gabapentin coadministration and dosing/spacing strategies that are not supported by the provided FDA label excerpts for magnesium sulfate in 5% dextrose injection (IV-only, specific obstetric indication, and monitoring/toxicity warnings). This mismatch could lead to unsafe use outside the label context and omission of key monitoring/maximum dosing/toxicity management details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are about gabapentin and oral magnesium supplements (interactions, dosing, timing) that are not addressed by the provided magnesium sulfate IV label. Key label-specific dosing/route/monitoring/toxicity details are omitted.
Suggested Improvement
Restrict claims to what the provided label excerpt supports for magnesium sulfate in 5% dextrose injection (IV-only; indication for pre-eclampsia/eclampsia; renal insufficiency precautions; serum monitoring; toxicity/maximum dosing; pregnancy duration fetal harm; listed drug classes affecting renal magnesium losses). Remove gabapentin-specific interaction, dosing, and timing statements unless the gabapentin label text is provided and evaluated.